(Q37984612)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339615%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Novel targets for VEGF-independent anti-angiogenic drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339615%20AND%20SRC:MED&resulttype=core&format=json

Maria Gabriella Ferrandina

23 January 2020

main subject

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

author

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339615%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

0 references

2

Giovanni Scambia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339615%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Marco Petrillo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339615%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

language of work or name

English

0 references

publication date

20 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339615%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

23 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339615%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339615%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339615%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

451-472

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339615%20AND%20SRC:MED&resulttype=core&format=json

Hallmarks of Cancer: The Next Generation

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

PDGF and vessel maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

The FGF family: biology, pathophysiology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Ligand-independent activation of vascular endothelial growth factor receptor 1 by low-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase II study of sunitinib in men with advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Molecular regulation of vessel maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Transient blood transfusion reaction masquerading as a post-transplantation lymphoproliferative disorder mimicking acute leukemia cutis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Development of c-MET pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Angiopoietin 1 is mitogenic for cultured endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Angiopoietin-2 is implicated in the regulation of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Expression and function of angiopoietin-1 in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Update on therapy of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

The emerging role of TGF-beta superfamily coreceptors in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

TGF-beta signaling in tumor suppression and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

ALK1 as an emerging target for antiangiogenic therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Molecular cloning and characterization of the human and porcine transforming growth factor-beta type III receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Endoglin in angiogenesis and vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Emerging role of endothelin-1 in tumor angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Inhibitory effect of endothelin A receptor blockade on tumor growth and liver metastasis of a human gastric cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Overexpression of the EphA2 tyrosine kinase in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Predicting the sites of metastases from lung cancer using molecular biologic markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

EphA2 expression is associated with aggressive features in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Over-expression of Ephb4 is associated with carcinogenesis of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

The multifaceted role of Notch in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Notch signaling, gamma-secretase inhibitors, and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.661715

10.1517/13543784.2012.661715

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339615%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference